Drugs / [18F]NAV4694
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT01812213 | Mar 2013 → Nov 2017 | cognitive impairment with or without cerebellar ataxia | Navidea Biopharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01680588 | Aug 2012 → Dec 2018 | Alzheimer disease | Navidea Biopharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT00991419 | Feb 2010 → Aug 2011 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01886820 | Jun 2013 → Jun 2018 | Alzheimer disease | Navidea Biopharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]NAV4694 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01812213 ↗ |
| Known as | [18F]AZD4694 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00991419 ↗ |
| Modality | Diagnostic / imaging agent | “[18F]AZD4694 PET Ligand” NCT00991419 ↗ |
| Route | Intravenous | “Single intravenous injection of 8.1 millicuries of [18F]NAV4694” NCT01680588 ↗ |